Innovative Technology
- The core technology of the platform lies in the use of Peptide Asparaginyl Ligases (PALs) to conjugate active drugs or any other payloads to proteins.
- Singzyme's platform for antibodies and nanobodies engineering and conjugation provides a one- stop solution to the problems faced by Antibody Drug Conjugates developers, stemming from their manufacturing process. Singzyme provides an integrated, high-speed, precision bio-manufacturing platform for ADCs and other bioconjugates.
Peptide Asparaginyl Ligases (PAL)
Use of peptide ligases for site-specific conjugation
Our platform leverages peptide ligases to achieve precise, site-specific conjugation with unmatched control.
A family of enzymes for combinatorial conjugation
We offer a versatile family of ligases enabling a broad range of conjugation strategies across different payloads and formats.
Up to 20,000 x faster reaction than other enzymes
- Our ligases catalyze conjugation reactions up to 20,000 times faster than traditional enzymatic methods, accelerating manufacturing timelines.
Minimal footprint on the final product
- The ligation process leaves only a minimal, non-immunogenic footprint, preserving the native structure of the therapeutic.
Low impact on antibody activity/tumour penetration
Conjugation preserves antibody binding and optimizes tumor penetration for superior therapeutic efficacy.
About Us
Applications
- Cancer immunotherapy
- Controlled Drug to Antibody Ratio
- Homogenous Product
- One Step process
- Faster and cheaper production of effective antibody-drug-conjugates
- Minimal footprint on the final product
- Attach Multiple payloads with high efficiency
- Imaging for disease diagnosis
- Ultra-fast production of radiopharmaceuticals for PET scan imaging (Nanobodies or mAbs)
- Minimal radioactive waste due to the highest conjugation efficiency.
- Lower toxicity (Low Kidney retention)